Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Collaborative Arrangements - Aggregate VIE Financial Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Jun. 04, 2015
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Provision for income taxes	$ 18,130	$ 30,131	$ 23,615	$ 30,430
Net (income) loss attributable to noncontrolling interest	(28,374)	32,144	(33,903)	32,242
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:
Restricted cash and cash equivalents (VIE)	70,513		70,513		$ 78,910
Prepaid expenses and other current assets	56,256		56,256		50,935
Intangible assets	284,340		284,340		284,340
Goodwill	50,384		50,384		50,384
Other assets	14,203		14,203		6,912
Accounts payable	51,302		51,302		74,942
Other current liabilities	275,165		275,165		305,820
Deferred tax liability, net	132,810		132,810		110,439
Other liabilities	30,648		30,648		31,778
Noncontrolling interest	187,491		187,491		153,661
BioAxone Biosciences Inc
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Contingent consideration, liability	28,700		28,700		28,000
Parion Sciences, Inc
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Provision for income taxes	17,500		20,600
Contingent consideration, liability	231,400		231,400		179,000
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:
Intangible assets						$ 255,300
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
Loss attributable to noncontrolling interest before provision for income taxes	2,835	1,293	3,674	1,579
Provision for income taxes	17,511	29,653	20,573	29,590
(Increase) decrease in fair value of contingent milestone and royalty payments	48,720	(1,198)	58,150	(1,073)
Net (income) loss attributable to noncontrolling interest	(28,374)	32,144	(33,903)	32,242
Variable Interest Entity, Consolidated, Carrying Amount, Assets and Liabilities, Net:
Restricted cash and cash equivalents (VIE)	70,513		70,513		78,910
Prepaid expenses and other current assets	3,001		3,001		3,138
Intangible assets	284,340		284,340		284,340
Goodwill	19,391		19,391		19,391
Other assets	383		383		455
Accounts payable	1,129		1,129		676
Taxes payable	11,723		11,723		24,554
Other current liabilities	7,059		7,059		7,100
Deferred tax liability, net	132,810		132,810		110,438
Other liabilities	310		310		300
Noncontrolling interest	187,491		187,491		$ 153,661
Variable Interest Entity, Primary Beneficiary \| BioAxone Biosciences Inc
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
(Increase) decrease in fair value of contingent milestone and royalty payments	320	423	750	548
Variable Interest Entity, Primary Beneficiary \| Parion Sciences, Inc
Variable Interest Entity, Primary Beneficiary, Does Not Hold Majority Voting Interest, Disclosures [Abstract]
(Increase) decrease in fair value of contingent milestone and royalty payments	$ 48,400	$ (1,621)	$ 57,400	$ (1,621)